TK216 (C09-1074-839)

InformationTK216 TK216 is a potent inhibitor targeting E26 transformation specific (ETS) factors via blocking the protein-protein interaction with RNA helicases. TK216 exhibits antilymphoma activity.TargetsETSIn vitroTK-216 demonstrates an antitumor activity across several lymphoma cell lines. Synergistic activity is observed when TK-216 is combined with the BCL2 inhibitor venetoclax and with the immunomodulatory drug lenalidomide.In vivoTK-216 demonstrates an antitumor activity in vivo. TK-216 interferes with protein interactions of ETS family members SPIB, in activated B-cell–like type diffuse large B-cell lymphomas, and SPI1, in germinal center B-cell–type diffuse large B-cell lymphomas.Cell Research(from reference)Cell lines：ABC-DLBCL, GCB-DLBCL, MCL, MZL, CLL, primary mediastinal large B-cell lymphoma, cutaneous T-cell lymphoma, PTCL-NOS, ALCL, canine DLBCL Concentrations：50 nM Incubation Time：24 h, 48 h, 72 h. Specification: 10mM in DMSO Molecular Formula: C19H15Cl2NO3 Molecular Weight: 376.23 PubChem CID: 121268274